Initial Statement of Beneficial Ownership (3)
November 16 2022 - 4:17PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
English Edward C |
2. Date of Event Requiring Statement (MM/DD/YYYY)
11/9/2022
|
3. Issuer Name and Ticker or Trading Symbol
Xilio Therapeutics, Inc. [XLO]
|
(Last)
(First)
(Middle)
828 WINTER STREET, SUITE 300 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) Principal Accounting Officer / |
(Street)
WALTHAM, MA 02451
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 6002 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (right to buy) | (1) | 2/7/2031 | Common Stock | 16428 | $5.89 | D | |
Stock Option (right to buy) | (2) | 3/10/2031 | Common Stock | 6891 | $5.89 | D | |
Stock Option (right to buy) | (3) | 6/16/2031 | Common Stock | 20828 | $10.07 | D | |
Stock Option (right to buy) | (4) | 7/22/2030 | Common Stock | 9050 | $5.51 | D | |
Stock Option (right to buy) | (5) | 2/21/2032 | Common Stock | 20200 | $12.66 | D | |
Explanation of Responses: |
(1) | The option was granted on February 8, 2021. On March 1, 2021, 1/48th of the shares underlying the option vested with the remainder scheduled to vest in equal monthly installments on the 1st day of each month thereafter through February 1, 2025. |
(2) | The option was granted on March 11, 2021. On April 1, 2021, 1/48th of the shares underlying the option vested with the remainder scheduled to vest in equal monthly installments on the 1st day of each month thereafter through March 1, 2025. |
(3) | The option was granted on June 17, 2021. On July 1, 2021, 1/48th of the shares underlying the option vested with the remainder scheduled to vest in equal monthly installments on the 1st day of each month thereafter through June 1, 2025. |
(4) | The option was granted on July 23, 2020. On September 30, 2020, 25% of the shares underlying the option vested with the remainder scheduled to vest in equal monthly installments on the last day of each month thereafter through September 30, 2023. |
(5) | The option was granted on February 22, 2022. On March 1, 2022, 1/48th of the shares underlying the option vested with the remainder scheduled to vest in equal monthly installments on the 1st day of each month thereafter through February 1, 2026. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
English Edward C 828 WINTER STREET SUITE 300 WALTHAM, MA 02451 |
|
| Principal Accounting Officer |
|
Signatures
|
/c/ Edward C. English | | 11/16/2022 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From Sep 2023 to Sep 2024